医学
2型糖尿病
胰高血糖素样肽1受体
糖尿病
不利影响
兴奋剂
内科学
胰高血糖素样肽-1
内分泌学
受体
作者
Hertzel C. Gerstein,Naveed Sattar,Julio Rosenstock,Chinthanie Ramasundarahettige,Richard E. Pratley,Renato D. Lópes,Carolyn S.P. Lam,Nardev S. Khurmi,Laura Heenan,Stefano Del Prato,Leanne Dyal,Kelley R. Branch
标识
DOI：10.1056/nejmoa2108269
摘要
Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular events among persons with type 2 diabetes. The effect of an exendin-based GLP-1 receptor agonist, efpeglenatide, on cardiovascular and renal outcomes in patients with type 2 diabetes who are also at high risk for adverse cardiovascular events is uncertain.
科研通智能强力驱动
Strongly Powered by AbleSci AI
爱静静
Polymer72
我是站长才怪
tuanheqi
Yoanna_UTHSC
细心的冷雪
帅气的如豹
橘海万青
梁朝伟
qq1083716237
Hayat
大佬
简单从丹
充电宝
VDC
wax
07
丘比特
yizhilaohuli
持卿
皖公网安备34019202002308
